BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH: Cardionovum GmbH announced today that it has initiated in vivo testing of its second drug-eluting balloon (DEB) RESTORE™. The Company is currently marketing a line of CE-marked paclitaxel-coated DEBs for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.
